Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.

NCT07040943 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07040943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07040943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.
Lead sponsor
West China Hospital
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2025
Completion date
July 20, 2026
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

interleukin, mrna vaccine, refractory malignant solid tumors